Kimmtrak

Tebentafusp, the active ingredient in Kimmtrak, is a bispecific T‑cell engager (ImmTAC) presented as an intravenous solution for infusion use. It is indicated for the treatment of metastatic uveal melanoma in adult patients whose tumors express the HLA‑A*02:01 allele. It works by directing patient T‑cells to recognize and destroy melanoma cells expressing the gp100 peptide.

GNH USA supplies Kimmtrak as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products.

Kimmtrak is indicated for metastatic uveal melanoma, a rare ocular cancer that has spread to distant sites. - Metastatic uveal melanoma: improves overall survival in adult patients with HLA‑A*02:01‑positive disease

Tebentafusp may cause a range of adverse reactions, most of which are related to its immunomodulatory activity.

Common Side Effects: - Infusion-related reactions: fever, chills, flushing, or hypotension. - Cytokine release syndrome (mild): fatigue, nausea, or headache. - Rash or skin erythema: localized redness.

Serious or Rare Side Effects: - Severe cytokine release syndrome: high‑grade systemic inflammation. - Capillary leak syndrome: hypotension and edema. - Neurotoxicity or cardiac events: confusion, seizures, arrhythmias, or myocardial injury.

When using Tebentafusp, clinicians should observe specific safety measures to minimise risks associated with its immunologic activity. - Monitor for cytokine release syndrome: assess vital signs before, during, and after infusion. - Pre‑medicate with antihistamines and antipyretics: reduce infusion‑related reactions. - Evaluate cardiac function: baseline ECG and periodic monitoring for arrhythmias. - Check liver function tests: detect early hepatic toxicity. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tebentafusp can interact with other therapies that affect immune function or cardiovascular stability.

Major Interactions (Avoid): - Concurrent use with other T‑cell engaging immunotherapies: may amplify immune activation and toxicity. - Live vaccines: risk of uncontrolled infection due to immune modulation. - Strong immunosuppressants (e.g., high‑dose steroids): may reduce therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Concomitant corticosteroids: may blunt cytokine release but require dose adjustment. - Anticoagulants: monitor for bleeding if capillary leak occurs. - Antihistamines: may mask early infusion reactions; observe patient closely.